Browsing by Author "Mendes-Bastos, P"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- A dermatosis of pregnancyPublication . Brás, S; Oliveira, A; Mendes-Bastos, P; Amaro, C
- Dermoscopic and reflectance confocal microscopic presentation of relapsing eccrine porocarcinomaPublication . Pinheiro, R; Oliveira, A; Mendes-Bastos, P
- Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic DermatitisPublication . Paller, AS; Ladizinski, B; Mendes-Bastos, P; Siegfried, E; Soong, W; Prajapati, VH; Lio, P; Thyssen, JP; Simpson, EL; Platt, AM; Raymundo, EM; Liu, J; Calimlim, BM; Huang, X; Gu, Y; Hu, X; Yang, Y; Su, JC; Zheng, M; Yamamoto-Hanada, K; Teixeira, HD; Irvine, ADImportance: Atopic dermatitis onset usually occurs in childhood. Persistence of disease into adolescence and adulthood is common. It is important to evaluate new treatment options in adolescents because of the high unmet need in this population. Objective: To assess the efficacy and safety of upadacitinib to treat moderate-to-severe atopic dermatitis in adolescents. Design, setting, and participants: Prespecified analysis of adolescents enrolled in 3 randomized, double-blind, placebo-controlled phase 3 clinical trials in more than 20 countries across Europe, North and South America, Oceania, the Middle East, and the Asia-Pacific region from July 2018 through December 2020. Participants were adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis. Data analysis was performed from April to August 2021. Interventions: Patients were randomized (1:1:1) to once-daily oral upadacitinib 15 mg, upadacitinib 30 mg, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up). Main outcomes and measures: Safety and efficacy, including at least a 75% improvement in the Eczema Area and Severity Index from baseline and validated Investigator Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear) at week 16 (coprimary end points). Results: A total of 552 adolescents (290 female; 262 male) were randomized. Mean (SD) age was 15.4 (1.8), 15.5 (1.7), and 15.3 (1.8) years for adolescents in Measure Up 1, Measure Up 2, and AD Up, respectively. In Measure Up 1, Measure Up 2, and AD Up, respectively, a greater proportion of adolescents (% [95% CI]) achieved at least 75% improvement in the Eczema Area and Severity Index at week 16 with upadacitinib 15 mg (73% [63%-84%], 69% [57%-81%], 63% [51%-76%]), and upadacitinib 30 mg (78% [68%-88%], 73% [62%-85%], 84% [75%-94%]), than with placebo (12% [4%-20%], 13% [5%-22%], 30% [19%-42%]; nominal P < .001 for all comparisons vs placebo). Similarly, a greater proportion of adolescents treated with upadacitinib achieved a validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 at week 16 and improvements in quality of life with upadacitinib than with placebo. Upadacitinib was generally well tolerated in adolescents. Acne was the most common adverse event, and all acne events were mild or moderate. Conclusions and relevance: In this analysis of 3 randomized clinical trials, upadacitinib was an effective treatment for adolescents with moderate-to-severe atopic dermatitis, with an acceptable safety profile.
- Epidemiology of Psoriasis in Portugal: A Population-Based StudyPublication . Torres, T; Filipe, P; Menezes Brandão, F; Figueiredo, A; Pinto Soares, A; Sousa Basto, A; Rebelo, C; Correia, O; Ferreira, P; Brasileiro, A; Mendes-Bastos, P; Paiva-Lopes, MJ; Marques Pinto, G; Severo, M; Mendonça, D; Oliveira, P; Selores, M; Massa, A; Pereira, M; Tavares Bello, R; Portuguese Society of Dermatology and Venereology, On behalf of the Portuguese Psoriasis Group of theIntroduction: Psoriasis is a common, chronic, and inflammatory skin disorder with a high personal, social and economic burden and important implica-tions for healthcare systems. The aim of this study was to provide an epidemiological characterization of individuals with psoriasis in Portugal.Material and Methods: A large observational, cross-sectional, nationwide, population-based survey study developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology (GPP-SPDV). A structured questionnaire was designed and applied by experienced inter-viewers to a random, representative sample of Portuguese individuals with psoriasis and/or psoriatic arthritis. Patients were considered to have psoriasis if they replied positively to one of the following questions: “Does any physician have ever diagnosed you with psoriasis?” or “Do you have a skin disorder characterized by scaling, reddish skin lesions located in the elbows/knees/scalp?”.Results: A total of 6381 individuals were interviewed, of which 283 met the criteria for psoriasis, corresponding to a prevalence rate of 4.4% (95% CI 3.95 – 4.98). Out of the participants that met psoriasis criteria, 24% had suggestive signs/symptoms but did not have a clinical diagnosis established and were not being monitored by a physician. Although more than 70% of participants had active disease (scaling, erythema, or pruritus) and one third had joint symptoms, only 12% were on systemic treatment. Fifty percent of participants with psoriasis (n = 139) had relevant comorbidities (most frequently depression/anxiety and cardiometabolic diseases). Sixteen percent of participants with psoriasis (n = 46) reported that psoriasis interfered with their daily activities (median impact of 5 in a 0 – 10 scale) and 12% mentioned the disease had an impact in their sexual life (median impact of 5 in a 0 – 10 scale). Conclusion: The results of this study suggest that the prevalence rate of psoriasis is likely to be high in Portugal, and several gaps exist at different levels of healthcare delivery to these patients, from diagnosis to treatment. This study provides important data for the future planning of interventions targeting the improvement of psoriasis care in Portugal.
- Quality of Life and characterization of patients with atopic dermatitis in Portugal - QUADEP studyPublication . Carvalho, D; Aguiar, P; Mendes-Bastos, P; Palma-Carlos, A; Freitas, J; Ferrinho, POBJECTIVES: To investigate the quality of life (QoL) and to characterize patients with atopic dermatitis (AD) in Portugal. METHODS: This was a cross-sectional study, including patients with AD and other eczemas. Skindex-29, Skindex-teen and Childhood Atopic Dermatitis Impact Scale (CADIS) were the instruments used to assess QoL in adults, teenagers, and children respectively. Complementarily, the SF-12 was used and disease severity was evaluated through Patient-Oriented SCORAD (PO-SCORAD). Odds Ratio (OR) were performed to measure associations with QoL. SPSS statistics 95% confidence intervals and values of p<0.05 were considered statistically significant. RESULTS: 162 participants were included, aging 0.5-74 years. We found that 37.3% of AD patients consider their disease as disabling and more than half of AD patients feel stigmatized by society. The mean Skindex score for AD was 39.68, and 44% patients presented a severe QoL impact. "Symptoms" was the most affected category in adults. Moderate to severe AD patients were 87% of the sample. Regarding the factors that most influenced worse QoL in AD, with increasing age, the Skindex score is likely to increase (OR: 1.03 [95%CI 1.00-1.06]). "Consider having disability" was also associated, OR: 6.72 (95%CI 2.56-17.63). With increasing affected body area and edema, the QoL worsens (OR: 1.07 [95%CI 1.03-1.11] and OR: 2.04 [95%CI 1.23-3.40], respectively). CONCLUSIONS: This is the first study with QoL data about AD patients in Portugal, revealing an expected negative impact. More awareness-raising activities are needed to increase literacy, decrease the stigma, and consequently to address some impacted factors in AD patients' QoL.